Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A person's susceptibility to papillary thyroid cancer may be determined by variations in telomere lengthening genes.

2.

Invest in generics as a lesson from the shortages of chemotherapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

5.

Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot